Reducing Mortality and Hospitalization in Heart Failure: New Guidelines and New and Emerging Treatments for HFpEF and HFrEF
November 15, 2022
November 15, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.
This activity is supported by educational grants from Alexion Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, Merck & Co., Inc., Novo Nordisk Inc., and Novartis Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
All other health care professionals completing this course will be issued a statement of participation.
The primary target audiences for the HCP activity are Cardiologists, primary care physicians, nurse practitioners, and physicians
Statement of Need/Program Overview
Despite advances in heart failure (HF) treatment over the past decade, the disease is still associated with high costs and high rates of morbidity, hospitalization, and mortality. In 2021, an update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure was published and yet the treatment course remains confusing for many clinicians. Research is also rapidly emerging on novel therapies for both HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF), including anti-diabetic agents that have shown cardiovascular benefits.
In this program a panel of expert cardiologists will navigate these guideline-concordant treatment approaches to promote effective care of HF and optimization of pharmacotherapy. Panelists will review the latest updates to the treatment guidelines and the rationales for those changes, along with clinical trial data related to HFpEF and HFrEF. Clinicians will be prepared to address barriers to guideline-directed medical therapy in effort to reduce mortality rates and improve quality of life for their patients with HF.
After completing this activity, the participant should be better able to:
- Explain the rational for important changes in the 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment
- Identify HF patients who should receive ARNI/ACE/ARB as first line treatment, and those who should receive a SGLT2 inhibitors as part as therapy intensification newer HF agents with efficacy in reducing mortality and hospitalization rates in patients with HF
- Describe the mechanisms of action of newly approved agents for the management of HF and how they relate to HF pathophysiology (ARNI and SGLT2 inhibitors)
- Discuss recent clinical trial data from emerging agents that have demonstrated efficacy in the treatment of HFrEF and HFpEF
Martha Gulati MD MS FACC FAHA FASPC FESC
President-American Society for Preventive Cardiology
Director, Preventive Cardiology
Associate Director, Barbra Streisand Women’s Heart Center
Associate Director, Preventive and Cardiac Rehabilitation Center
Anita Dann Friedman Endowed Chair in Women’s Cardiovascular Medicine & Research
Smidt Heart Institute
Scott Soloman, MD
Edward D. Frohlich Distinguished Chair, Professor of Medicine
Harvard Medical School
Director of Clinical Trials Outcomes Center and the Cardiac Imaging Core Laboratory
Brigham and Women’s Hospital
Gregg Fonarow MD
Eliot Corday Professor of Cardiovascular Medicine and Science
Director, Ahmanson-UCLA Cardiomyopathy Center
Co-Director, UCLA Preventative Cardiology Program
Chief, UCLA Division of Cardiology (Interim)
David Geffen School of Medicine, UCLA
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Martha Gulati MD MS FACC FAHA FASPC FESC, has nothing to disclose.
- Scott Soloman, MD
- Consulting Fee (e.g., Advisory Board): Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boeringer-Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Puretech Health
- Contracted Research: Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, US2.AI
- Gregg Fonarow MD
- Consulting Fee: Abbott, Amgen, AstraZeneca, Cytokinetics Egnite, Janssen, Medtronic, Merck Novartis, Pfizer, Urovant
- Research: NIH
- Speakers Bureau: Novartis
The planners and managers have the following relevant financial relationships with ineligible companies:
Lindsay Borvansky, has nothing to disclose.
Andrea Funk, has nothing to disclose.
Liddy Knight, has nothing to disclose.
Ashley Cann, has nothing to disclose.
Lauren Sinclair, has nothing to disclose.
Carole Drexel, has nothing to disclose.
Colleen Hefner, has nothing to disclose.
Caroline Laurendeau, has nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@PlatformQHealth.com with the subject line “Data Request”